Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study

Paul M McKeigue 1 3 , Amanda Weir 3 , Jen Bishop 3 , Stuart J McGurnaghan 2 , Sharon Kennedy 7 , David McAllister 4 3 , Chris Robertson 5 3 , Rachael Wood 7 , Nazir Lone 1 , Janet Murray 3 , Thomas M Caparrotta 2 , Alison Smith-Palmer 3 , David Goldberg 3 , Jim McMenamin 3 , Colin Ramsay 3 , Sharon Hutchinson 6 3 , Helen M Colhoun 2 3

1 Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, Scotland. PM - Professor of Genetic Epidemiology and Statistical Genetics. NL - Clinical Senior Lecturer in Critical Care

2 Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh EH4 2XUC, Scotland. HC - Axa Chair in Medical Informatics and Epidemiology. TC - Sir George Alberti Doctoral Fellow in Pharmacoepidemiology.

3 Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow G2 6QE
4 Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens,

Glasgow G12 8RZ. DM - Wellcome Trust Intermediate Clinical Fellow and Beit Fellow
5 Department of Mathematics and Statistics, University of Strathclyde, 16 Richmond
Street, Glasgow G1 1XQ. CR - Professor of Public Health Epidemiology

6 School of Health and Life Sciences, Glasgow Caledonian University. SH - Professor of Epidemiology and Population Health

7 NHS Information Services Division (Public Health Scotland), Gyle Square, 1 South Gyle Crescent, Edinburgh, EH12 9EB. RW - Consultant in Maternal and Child Health.

On behalf of Public Health Scotland COVID-19 Health Protection Study Group

Abstract

Background– The objectives of this study were to identify risk factors for severe COVID-19 and to lay the basis for risk stratification based on demographic data and health records.

Methods – The design was a matched case-control study. Severe cases were all those with a positive nucleic acid test for SARS-CoV-2 in the national database who had entered a critical care unit or died within 28 days of the first positive test. Ten controls per case matched for sex, age and primary care practice were selected from the population register. All diagnostic codes from the past five years of hospitalisation records and all drug codes from prescriptions dispensed during the past nine months were extracted. Rate ratios for severe COVID-19 were estimated by conditional logistic regression.

Findings – In a logistic regression using the age-sex distribution of the national population, the odds ratios were 2.26 for a 10-year increase in age and 1.86 for male sex. In the case-control analysis, the strongest risk factor was residence in a care home, with rate ratio (95% CI) 14.9 (12.7, 17.5). Univariate rate ratios (95% CIs) for conditions listed by public health agencies as conferring high risk were 4.88 (3.26, 7.31) for Type 1 diabetes, 2.58 (2.30, 2.88) for Type 2 diabetes, 2.40 (2.14, 2.70) for ischemic heart disease, 3.90 (3.52, 4.32) for other heart disease, 3.10 (2.81, 3.42) for chronic lower respiratory tract disease, 12.1 (8.4, 17.4) for chronic kidney disease, 5.5 (4.8, 6.2) for neurological disease, 4.70 (2.90, 7.62) for chronic liver disease and 4.11 (2.72, 6.21) for immune deficiency or suppression.

72% of cases and 35% of controls had at least one listed condition (50% of cases and 9% of controls under age 40). Severe disease was associated with encashment of at least one prescription in the past nine months and with at least one hospital admission in the past five years [rate ratios 16.6 (13.3, 20.6)] and 5.6 (5.0, 6.2) respectively] even after adjusting for the listed conditions. In those without listed conditions significant associations with severe disease were seen across many hospital diagnoses and drug categories. Age and sex provided 1.81 bits of information for discrimination. A model based on demographic variables, listed conditions, hospital diagnoses and prescriptions provided an additional 1.5 bits (C-statistic 0.839).

Conclusions – Along with older age and male sex, severe COVID-19 is strongly associated with past medical history across all age groups. Many comorbidities beyond the risk conditions designated by public health agencies contribute to this. A risk classifier that uses all the information available in health records, rather than only a limited set of conditions, will more accurately discriminate between low-risk and high-risk individuals who may require shielding until the epidemic is over.

Background

Case series from many countries have suggested that in those with severe COVID-19 the prevalence of diabetes and cardiovascular disease is higher than expected. For example in a large UK series the commonest co-morbidities were cardiac disease, diabetes, chronic pulmonary disease and asthma [1]. However there are also anecdotal reports of apparently healthy young persons succumbing to disease [2].

Quantification of the risk associated with characteristics and co-morbidities has been limited by the lack of comparisons with the background population [3–5]. Two recent studies in the UK have included population comparators and have reported associations of in hospital test positive persons and COVID-19 death in hospital with co-morbidities including diabetes, asthma and heart disease [6,7]. These studies have focused on conditions presumptively listed by public health agencies as increasing risk for COVID-19 based on case series data.

Here we examine the frequency of sociodemographic factors and these listed conditions in all people with severe COVID-19 disease in Scotland compared to matched controls from the general population. In those without listed conditions we report a systematic examination of the hospitalisation record and prescribing history in severe COVID-19 cases compared to controls. The objectives were to identify risk factors for severe COVID-19 and to lay the basis for risk stratification based on a predictive model.

Methods

Case definition

The Electronic Communication of Surveillance in Scotland (ECOSS) database captures all virology testing in all NHS laboratories nationally. Individuals testing positive for nucleic acid for SARS-CoV-2 up to 30 April 2020 in ECOSS were ascertained. Using the Community Health Index (CHI) identifier contained in ECOSS (the CHI number is a unique identifier used in all care systems in Scotland) linkage to other datasets was carried out. Hospital admissions from the time of testing were obtained from the RAPID database a daily return of current hospitalisations each day. Admissions to critical care were obtained from the Scottish Intensive Care Society and Audit Group (SICSAG) database that covers admissions to critical care [comprising adult intensive care units (ICUs), high dependency units (HDUs) and combined ICU / HDU units] across Scotland and has returned a daily census of patients in critical care from the beginning of the COVID-19 epidemic. Death registrations up to 4 May 2020 were obtained from linkage to the National Register of Scotland.

Severe or fatal COVID-19 was defined by a record of entering critical care in the SICSAG database, or death within 28 days of a positive nucleic acid test, regardless of the cause of death given on the death certificate. By restricting the case definition to those cases that were fatal or received critical care, we ensured complete ascertainment of all test-positive cases that were severe enough to have been fatal without critical care, whatever selection policies may have determined admission to hospital or entry to critical care.

Matched controls

For each test-positive case, we ascertained ten matched controls of the same sex, one-year age band and registered with the same primary care practice who were alive on the date of the first test in the case using the Community Health Index (CHI) database. As this is an incidence density sampling design, it is possible and correct for an

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

55

56

57

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

> individual to appear in the dataset more than once, initially as a control and subsequently as a case.

,

85

87

88

89

90

91

92

93

94

96

97

98

qq

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

Demographic data

Residence in a care home was ascertained from the CHI database. Socioeconomic status was assigned as the Scottish Index of Multiple Deprivation (SIMD), an indicator based on postal code. Ethnicity was assigned based on applying a name classification algorithm (ONOMAP) [8] to the names in the CHI database. For 54% of cases and 28% of controls self-assigned ethnicity, based on the categories used in the Census, had been recorded in Scottish Morbidity Records (SMR). Cross-tabulation of 28011 records for which both name classification and SMR records of ethnicity were available showed that the ONOMAP algorithm had sensitivity of 93% and specificity of 99.57% for classifying South Asian ethnicity, but misclassified most of those who identified as African, Caribbean or Black.

Morbidity and drug prescribing

For all cases and controls, ICD-10 diagnostic codes were extracted from the last five years of hospital discharge records in the Scottish Morbidity Record (SMR01), excluding records of discharges less than 25 days before testing positive for SARS-CoV-2 and using all codes on the discharge. Diagnostic coding under ICD chapters 5 (Mental, Behavioural and Neurodevelopmental) and 15 (Pregnancy) is incomplete as most psychiatric and maternity unit returns are not captured in SMR01. British National Formulary (BNF) drug codes were extracted from the last year of encashed prescriptions, excluding those encashed less than 25 days before testing positive for SARS-CoV-2. The BNF groups drugs by 2-digit chapter codes. For this analysis prescription codes from chapters 14 and above, mostly for dressings and appliances but also including vaccines were grouped as "Other".

We began by scoring a specific list of conditions that have been designated as risk conditions for COVID-19 by public health agencies [9]. A separate list of conditions designates "clinically extremely vulnerable" individuals who have been advised to shield themselves completely since early in the epidemic: this list includes solid organ transplant recipients, people receiving chemotherapy for cancer, and people with cystic fibrosis or leukaemia. We did not separately tabulate these conditions as we expected these individuals to be underrepresented among cases if shielding was adequate.

The eight listed conditions were scored based on diagnostic codes in any hospital discharge record during the last five years, or encashed prescription of a drug for which the only indications are in that group of diagnostic codes. The R script included as supplementary material contains the derivations of these variables from ICD-10 codes and BNF drug codes. Diagnosed cases of diabetes were identified through linkage to the national diabetes register (SCI-Diabetes), with a clinical classification of diabetes type as Type 1, Type 2 or Other/Unknown. Cases of diabetes diagnosed since the last update of the register were identified through discharge codes and drug codes, and assigned to the diabetes type Other/Unknown category.

Statistical methods

To estimate the relation of cumulative incidence and mortality from COVID-19 to age and sex, logistic regression models were fitted to the proportions of cases and non-cases in the Scottish population, using the estimated population of Scotland in mid-year 2019 which were available by one-year age group up to age 90 years. To allow for possible non-linearity of the relationship of the logit of risk to age, we also fitted generalized

additive models, implemented in the R function gam::gam, with default smoothing function.

For the case-control study, all estimates of associations with severe COVID-19 were based on conditional logistic regression, implemented as Cox regression in the R function survival::clogit. Among those cases and controls without any of the pre-defined conditions we then further examined associations of ICD-10 and BNF chapter with severe COVID-19. Where an exclusion criterion such as having a pre-defined condition was applied to cases this was also applied to controls as otherwise subsequent association estimates would be incorrect. Where the sample of cases and controls is restricted, this will generate strata that contain no cases but these strata will be ignored by the conditional logistic regression model as they do not contribute to the conditional likelihood. With incidence density sampling, the odds ratios in conditional logistic regression models are equivalent to rate ratios. Note that odds ratios in a matched case control study are based on the conditional likelihood and the unconditional odds ratios calculable from the frequencies of exposure in cases and controls will differ from these and should not be used [10]. Although matching on primary care practice will match to some extent for associated variables such as care home residence, socioeconomic disadvantage and prescribing practice, the effects of these variables are still estimated correctly by the conditional odds ratios but with less precision than in an unmatched study of the same size [10].

To construct risk prediction models, we used stepwise regression alternating between forward and backward steps to maximize the AIC, implemented in the R function stats::step. The performance of the risk prediction model in classifying cases versus non-cases of severe COVID-19 was examined by 4-fold cross-validation. We calculated the performance calculated over all test folds using the C-statistic but also using the "expected information for discrimination" Λ expressed in bits [11]. The use of bits (logarithms to base 2) to quantify information is standard in information theory: one bit can be defined as the quantity of information that halves the hypothesis space. Although readers may be unfamiliar with the expected information for discrimination Λ , it has several properties that make it more useful than the C-statistic for quantifying increments in the performance of a risk prediction model [11]. A key advantage of using Λ is that contributions of independent predictors can be added. Thus in this study we can add the predictive information from a logistic model of age and sex in the general population to the predictive information provided by other risk factors from the case-control study matched for age and sex.

Results

Incidence and mortality from severe COVID-19 in the Scottish population

Figure 1 shows the relationships of incidence and mortality rates to age for each sex 170 separately. The relationship of mortality to age is almost exactly linear on a logit scale, 171 and the lines for male and female mortality are almost parallel. In models that included 172 age and sex as covariates, the odds ratio associated with a 10-year increase in age was 173 2.26 for all severe disease and 3.35 for fatal disease. The odds ratio associated with male 174 sex was 1.86 for all severe disease and 1.87 for fatal disease. For severe cases as defined 175 in this study, the sex differential is narrow up to about age 50 but widens between ages 176 50 and 70 years. Thus at younger ages the ratio of critical care admissions to total 177 fatalities is higher in women than in men, but that at later ages the ratio of critical 178 admissions to total fatalities is higher in men. 179

167 168

169

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

Risk factors

Sociodemographic factors

Table 1 shows univariate associations of demographic factors with severe disease. Residence in a care home was by far the strongest risk factor for severe disease. Higher risk of severe disease was also associated with socioeconomic deprivation. Associations with ethnicity are shown for the full dataset based on name classification and separately for the subset of cases and controls in whom ethnicity had been recorded in the Scottish Morbidity Record. With Whites as reference category, the rate ratio (95% CI) associated with South Asian ethnicity was 0.53 (0.37, 0.76) based on name classification and 0.81 (0.31, 2.10), based on the subset with SMR records. The numbers of cases in other non-White ethnic groups were too sparse to tabulate separately.

Factors derived from hospitalisation and prescribing records

Prevalence of the listed conditions in cases and controls by age band is shown in Table 2. 192 30 (50%) of the cases aged under 40 years had at least one listed condition, compared 193 with only 53 (9%) of the controls. In those aged 75+ years 976 (80%) of the cases and 194 5172 (43%) of the controls had at least one listed condition. The proportion with at 195 least one dispensed prescription was much higher in cases than in controls in each age 196 group. Among those aged under 40 years, 50 (83%) of the cases and 305 (51%) of the 197 controls had either a hospital admission in the last five years or a dispensed prescription 198 in the last year. 199

Over all age groups, 1599 (72%) of severe cases and 7701 (35%) of controls had at least one of the listed conditions. As shown in Table 3, all the listed conditions were more frequent in cases than controls. The rate ratio associated with type 1 diabetes was higher than that for type 2 diabetes. The rate ratio was 2.40 (2.14, 2.70) for ischemic heart disease compared to 3.90 (3.52, 4.32) for the broad category "other heart disease". In multivariate analysis ischemic heart disease was not independently associated with severity whereas other heart disease remained strongly associated.

Supplementary Tables 8 to 10 examine these associations by age group, with the 0-39 and 40-59 year age bands combined. All listed conditions were associated with severe disease in each age band. In those aged under 60 years, the rate ratio was 9.8 (5.2, 18.4) for Type 1 diabetes and 5.4 (3.9, 7.5) for Type 2 diabetes. The multivariate analyses shown in Table 3 and 8 to 10 show that overall and within each age group dispensing of any prescription in the past year and any admission to hospital in the past five years were strongly and independently associated with severe disease even after adjusting for care home residence and listed conditions. Table 4 shows that in each age group the proportion of fatal cases who had not had either a hospital admission in the last five years or a dispensed prescription in the last year was very low.

Systematic analysis of diagnoses associated with severe disease

The association of severe COVID-19 with prior hospital admission was examined further 218 by testing for association of hospitalisations at each ICD-10 chapter level with severe 219 COVID-19, among those without any of the listed conditions. These results are shown 220 in Table 5. In univariate analyses, almost all ICD-10 chapters, with the exception of 221 Chapters 8 (ear) and Chapter 15 (pregnancy) were associated with increased risk of 222 severe disease. Note that hospital diagnoses classified under the pregnancy chapter here 223 are derived from admissions with pregnancy related medical conditions to non-obstetric 224 units only, as obstetric returns are not in the SMR01 dataset. In a multivariate analysis 225 the strongest associations were with diagnoses in ICD chapter 2 (neoplasms). 226 Supplementary Table 11 extracts univariate associations with ICD-10 subchapters in 227

181 182

183

186

187

188

189

190

191

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

180

> those without any listed conditions. This table is filtered to show only subchapters for 228 which the univariate p-value is < 0.001 and where there are at least 50 cases and 229 controls with a diagnosis in this subchapter. This shows that many diagnoses are 230 associated with markedly higher risk of severe COVID-19. Past hospital diagnoses of 231 infections, pneumonia and acute respiratory diseases were strongly associated with 232 severe COVID-19. Cardiovascular diagnoses associated with COVID-19 were not limited 233 to heart disease but included also stroke and other circulatory disorders that are not 234 designated as risk conditions. 235

Associations of prescribed drugs with severe disease

As shown in Table 3 and supplementary tables 8 to 10, the strongest risk factor for severe disease, apart from residence in a care home, is the encashment of at least one prescription in the last year. The univariate rate ratio associated with this variable varies from 9.6 (6.9, 13.3) in those aged under 60 years to 40.3 (25.6, 63.3) in those aged 75 years and over. In a multivariate analysis adjusting for care home residence, any hospital admission and listed conditions, these rate ratios were reduced to 5.0 (3.5, 7.2) and 11.4 (7.1, 18.4) respectively. About one third of controls aged over 75 had not encashed a prescription in the previous year.

To investigate this further, we partitioned the "Any prescription" variable into indicator variables for each chapter of the British National Formulary, in which drugs are grouped by broad indication, and restricted the analysis to those without one of the listed conditions. Table 6 shows these associations. In univariate analyses, prescriptions in almost all BNF chapters were associated with severe disease. In a multivariate analysis of all chapters, most of these associations were weaker. The BNF chapters with the strongest independent associations with severe disease were chapters 1 (gastrointestinal) and 2 (cardiovascular). Other chapters associated with severe disease were chapters 4 (central nervous system), 9 (nutrition and blood) and 14+ (other, mostly dressings and appliances).

Construction of a multivariate risk prediction model

To evaluate the contribution of the listed conditions to risk prediction, and the incremental contribution of other information in hospitalisation and prescription records after assigning these conditions, predictive models were constructed from three sets of variables: a baseline set consisting only of demographic variables, a set that included indicator variables for each listed condition, and an extended set that included demographic, variables, indicator variables for listed conditions and indicator variables for hospital diagnoses in each ICD-10 chapter and prescriptions in each BNF chapter.

For each variable set, a stepwise regression procedure was carried out using alternating forward-backward selection. The variables retained with each variable set are shown in Table 12. Coefficients for specific conditions here should not be interpreted as effect estimates, as global variables for any hospital diagnosis and any listed condition have been included in the model. The predictive performance of the model chosen by stepwise regression was estimated by 4-fold cross-validation. Observed and predicted case status were compared within each stratum over all test folds. Table 7 shows that using the extended set increased the C-statistic from 0.782 to 0.839 and the expected information for discrimination Λ from 0.89 bits to 1.5 bits.

This estimate of 1.5 bits for the information conditional on age and sex obtained 2772 from the matched case-control study can be added to the information for discrimination 2773 1.81 bits obtained from the logistic regression on age and sex in the population using 2774 age and sex to estimate the total information for discrimination of a risk classifier that 275 would be obtained in the population as 3.31 bits. 276

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

> Figure 2 shows the distribution of the weight of evidence favouring case over control status from the model based on the extended variable set with a footnote explaining how Λ is derived. This shows, as expected for a multifactorial classifier, that the distributions are approximately Gaussian: there is no clear divide between high-risk and low-risk individuals of the same age and sex. Figure 3 shows the receiver operating characteristic curve with a footnote explaining its derivation from the distribution of the weights of evidence.

Discussion

Sociodemographic factors

This analysis confirms that risk for severe COVID-19 is associated with increasing age, male sex and socioeconomic deprivation. The slope of the relationship of severe disease (on the scale of log odds) to age is less steep than the slope of the relationship of fatal disease to age. Residence in a care home was associated with a 15-fold increased rate of severe COVID-19 in this age matched analysis, reduced to 7-fold by adjustment for listed conditions. This excess risk is likely to reflect both the spread of the epidemic in care homes and residual confounding by frailty.

Although the numbers of cases and controls of non-White ethnicity are small and the 293 assignment of ethnicity is incomplete, the results give some indication of the likely 294 upper bound of the absolute numbers of severe cases in non-White ethnic groups up to 295 now. The only non-White ethnic group with any sizeable numbers is the South Asian 296 category and we found no evidence of any elevation in risk in this group compared to 297 Whites. Reports from England [7] found elevation in risks for some non-White groups. 298 In the OpenSAFELY study risk ratios for fatal COVID-19 of 1.7 in those recorded as 299 Black and and 1.6 in those recorded as Asian, in comparison with those recorded as 300 White, persisted after adjustment for comorbidities and socioeconomic status. In a 301 study of risk factors for hospitalized disease in the UK Biobank cohort, adjustment for 302 health care worker status and other social variables attenuated but did not fully explain 303 the elevated crude risk ratios associated with non-White ethnicity [6,12]. The relative 304 socioeconomic position of ethnic groups in Scotland is different to that in England, so it 305 is plausible that the relation of health status to ethnicity will also differ. For example in 306 the 2011 Scottish Census 1.6% of the population reported South Asian ethnicity. 307 Among the 1.0% who identified as Pakistani or Bangladeshi the proportion living in the 308 most deprived neighbourhoods was not higher than the national average [13]. Future 309 work may allow more complete assignment of ethnicity and disaggregation of broad 310 categories based on continent of origin. 311

Co-morbidities

We have confirmed that the moderate risk conditions designated by the NHS and other 313 agencies [9] are associated with increased risk of severe COVID-19. However the rate 314 ratios associated with these conditions vary with age - for example the rate ratio 315 associated with diabetes is higher at younger ages. The rate ratios of 4.9 for Type 1 316 diabetes and 2.6 for Type 2 diabetes are broadly similar to those reported in UK 317 Biobank and in the OpenSAFELY studies. We confirm the higher risk with asthma and 318 chronic lung disease and liver disease reported in these and earlier studies. Of note other 319 heart disease is more strongly associated than ischaemic heart disease. This category 320 includes conditions such as atrial fibrillation, cardiomyopathies and heart failure. Over 321 all age groups, 72% of severe cases had at least one of these listed conditions. Among 322 cases and controls without these conditions, not surprisingly, neoplasms were associated 323 with severe COVID-19; we had omitted it from the pre-specified list as in the current 324

288 289

284

285

286

287

290

291

292

dataset we cannot separately identify those who are currently receiving chemotherapy or radiotherapy for whom shielding is advised. We have not attempted to estimate the risk associated with these conditions for which shielding is recommended, as the observed risk will depend on the adequacy of shielding rather than on the risk to those exposed to the epidemic. In patients without any listed conditions, further systematic evaluation of past hospitalisation history did not reveal a sparse set of underlying conditions; instead many diagnoses were associated with severe COVID-19.

Media reports of apparently healthy young people succumbing to severe COVID-19 have disseminated the message that all are at risk of disease whatever their age or health status. However we found that half of cases under 40 years had at least one of the listed conditions and among those who did not have one of these conditions, the proportions who had at least one prior hospitalisation or dispensed prescription were much higher in cases than in controls. In all age groups, very few of the fatal cases had not had either a hospital admission in the past five years or a dispensed prescription in the past year.

A striking finding of this study was the strong association of severe COVID-19 with having encashed at least one prescription in the past year, only partly explained by higher rates of prescribing among those with listed conditions. Partitioning of this association between BNF chapters, which represent broad indication-based drug classes, showed that the strongest association was with prescription of Chapter 1 drugs, prescribed for gastrointestinal conditions, which are not generally listed as risk factors for severe COVID-19. Also associated were those in the cardiovascular, nervous system and nutritional and blood chapters. Although it is likely that most associations of severe COVID-19 with drug prescribing are attributable to the indications for which these drugs were prescribed, or more diffuse frailty especially in older persons, causal effects of drugs or direct effects of polypharmacy on susceptibility cannot be ruled out. These associations are explored in an accompanying paper.

Relevance to policy

As lockdown restrictions are eased, there is general agreement that vulnerable individuals will require shielding, even if the restart of the epidemic can be slowed or suppressed by mass testing, contact tracing and isolation of those who test positive. The "stratify and shield" policy option [14], in which high-risk individuals comprising up to 15% of the population are shielded for a defined period while the epidemic is allowed to run relatively quickly in low-risk individuals until population-level immunity is attained, depends critically on informative risk discrimination. So too does the similarly named "segment and shield" option [15] which has the opposite objective of keeping transmissions low.

As awareness grows of how risk varies between individuals, individuals will seek 361 information about their own level of risk. A key implication of our results is that risk of 362 severe or fatal disease is multifactorial and that the rate ratio of 5.1 associated with a 363 20-year increase in age is far stronger than that associated with common diseases such 364 as Type 2 diabetes and asthma that are listed as conditions associated with high risk. A 365 corollary of this is that a crude classification based on assigning all persons with a listed 366 condition to a group for whom shielding is recommended will have poor specificity, as 367 one quarter of those aged 60-74 years in the population have at least one of the listed 368 conditions we examined. It will also exclude many people at high risk because they have 369 multiple risk factors each of small effect. The only way to optimize risk classification so 370 as to ensure equity with respect to risk is to construct a classifier that uses all available 371 information to assign a risk score. Our results show that this is possible in principle. 372 though for this preliminary study we have not used the full repertoire of machine 373 learning methods available for this type of problem. In Scotland it is technically 374 possible to use existing electronic health records to calculate a risk score for every 375

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

individual in the population, though more work would be required to develop this as a ³⁷⁶ basis for official advice and individual decisions. ³⁷⁷

Methodological strengths and weaknesses

Most reports of disease associations with COVID-19 have been case series. There have been few reports based on evaluating these associations in the population through cohort or case-control studies. With this matched case control design using incidence density sampling, we have been able to estimate rate ratios conditional on age and sex. An unpublished analysis from England explored the association of similar set of risk conditions with in-hospital COVID-19 deaths, but did not systematically evaluate the rest of the medical record including prescription records. Although we have records of encashment of prescriptions, we do not at present have access to other primary care data, which would contain additional information on morbidity and measurements such as body mass index. A strength of our study however is that hospital discharge diagnoses are coded to ICD-10 by trained coders, in contrast to the coding systems used in primary care databases that do not map to recognized disease classifications. Associations with ethnicity and other sociodemographic factors are not necessarily generalizable from Scotland to other populations.

This case-control study is limited to test-positive cases, excluding deaths with no record of a positive test where COVID-19 was mentioned on the death certificate as an underlying or contributing cause. Up to 13 May 2020 an additional 1200 such deaths had been reported by the National Records of Scotland. Future analyses of this study will include sensitivity analyses of the extent to which the results are changed by including these deaths, but linked data are not yet available to us. Apart from residential care home status, we do not expect most other risk factors to differ markedly between those who died from COVID-19 without being tested and those who died after testing.

Conclusion

This study confirms that risk of severe COVID-19 is associated with sociodemographic factors and with chronic conditions such as diabetes, asthma, circulatory disease and others. However the associations with pre-existing disease are not just with a small set of conditions that contribute to risk, but with many conditions as demonstrated by associations with past medical and prescribing history in relation to multiple physiological systems. As countries attempt to emerge from lockdown whist protecting vulnerable individuals, multivariate classifiers rather than crude rule-based approaches will be needed to define those most at risk of developing severe disease.

Declarations

Information governance

This study was conducted under approvals from the Privacy Advisory Committee ref 44/13 and Public Benefit Privacy Protection amendment 1617-0147. Datasets were de-identified before analysis.

Conflicts of interest

The authors declare no conflicts of interest.

10/30

402

378

379

380

381

382

383

384

385

387

388

389

390

391

392

393

394

395

396

398

399

400

401

410

411

412

413

414

415

416

	418
database,	419
er of	420
ID-19	421
ratories, and	422
	423
tudy	424
	425
¹ , Andy	426
y^1 , David	420
$\frac{1}{2}$ ennan ¹ ,	
anet	428
inet	429
ie ¹ , Lindsay o ¹ , Michelle	430
	431
Adam	432
$e \text{ Glass}^2$,	433
5 0 1	434
, 5 Cadogan	435
	436
Glasgow G2	437
	438
	439
the code	440
the code	440
	441
	442
L, et al.	443
RIC WHO	444
	445
	446
onavirus?	447
ık/health-	448
	449
	450
risk factors	451
ospective	452
566-3	453
A, et al.	454
RS-CoV-2	455
1581.	456
	457
	458
al of	459
	460
orales C, et	461
K Dichard	

Acknowledgements

We thank all staff in critical care units who submitted data to the SICSAG database, the Scottish Morbidity Record Data Team, the staff of the National Register of Scotland, the Public Health Scotland Terminology Services, the HPS COVID-19 Laboratory & Testing cell and the NHS Scotland Diagnostic Virology Laboratories, and Nicola Rowan (HPS) for coordinating this collaboration.

Public Health Scotland COVID-19 Health Protection Study Group

Alice Whettlock¹, Allan McLeod¹, Andrew Gasiorowski¹, Andrew Merrick¹, Andy McAuley¹, April Went¹, Calum Purdie¹, Colin Fischbacher¹, Colin Ramsay¹, David Bailey¹, David Henderson¹, Diogo Marques¹, Eisin McDonald¹, Genna Drennan¹, Graeme Gowans¹, Graeme Reid¹, Heather Murdoch¹, Jade Carruthers¹, Janet Fleming¹, Jade Carruthers¹, Joseph Jasperse¹, Josie Murray¹, Karen Heatlie¹, Lindsay Mathie¹, Lorraine Donaldson¹, Martin Paton¹, Martin Reid¹, Melissa Llano¹, Michelle Murphy-Hall¹, Paul Smith¹, Ros Hall¹, Ross Cameron¹, Susan Brownlie¹, Adam Gaffney², Aynsley Milne², Christopher Sullivan², Edward McArdle², Elaine Glass², Johanna Young², William Malcolm², Jodie McCoubrey ²

1 Health Protection Scotland (Public Health Scotland), Meridian Court, 5 Cadogan Street, Glasgow G2 6QE.

2 NHS National Services Scotland, Meridian Court, 5 Cadogan Street, Glasgow G2 6QE.

Supplementary material

The R and Rmarkdown scripts used to generate this article, which include the code used to derive variables, will be made available with this manuscript.

References

1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2020; 2020.04.23.20076042. doi:10.1101/2020.04.23.20076042

2. McGoogan C, Steafel E. Why are young, healthy people dying of coronavirus? The symptoms to look out for. The Telegraph. https://www.telegraph.co.uk/health-fitness/body/why-young-healthy-people-dying-coronavirus/; 2020.

3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395: 1054–1062. doi:10.1016/S0140-6736(20)30566-3

4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323: 1574–1581. doi:10.1001/jama.2020.5394

5. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine. 2020. doi:10.1056/NEJMoa2002032

6. Niedzwiedz CL, O'Donnell CA, Jani BD, Demou E, Ho FK, Celis-Morales C, et al. Ethnic and socioeconomic differences in SARS-CoV2 infection in the UK Biobank cohort study. medRxiv. 2020; 2020.04.22.20075663. doi:10.1101/2020.04.22.20075663

> 7. "The OpenSAFELY Collaborative", Williamson E, Walker AJ, Bhaskaran KJ, 464 Bacon S, Bates C, et al. OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. 466 medRxiv. 2020; 2020.05.06.20092999. doi:10.1101/2020.05.06.20092999

8. Lakha F, Gorman DR, Mateos P. Name analysis to classify populations by ethnicity in public health: Validation of Onomap in Scotland. Public Health. 2011;125: 688–696. doi:10.1016/j.puhe.2011.05.003

9. NHS. Who's at higher risk from coronavirus - Coronavirus (COVID-19). nhs.uk. https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk-fromcoronavirus/whos-at-higher-risk-from-coronavirus/;

10. Breslow NE, Day NE, Halvorsen KT, Prentice RL, Sabai C. Estimation of multiple relative risk functions in matched case-control studies. Am J Epidemiol. 1978;108: 299–307. doi:10.1093/oxfordjournals.aje.a112623

11. McKeigue P. Quantifying performance of a diagnostic test as the expected information for discrimination: Relation to the C-statistic. Stat Methods Med Res. 2019;28: 1841–1851. doi:10.1177/0962280218776989

12. Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C, et al. Modifiable and non-modifiable risk factors for COVID-19: Results from UK Biobank. medRxiv. 2020; 2020.04.28.20083295. doi:10.1101/2020.04.28.20083295

13. Walsh D, Buchanan D, Douglas A, Erdman J, Fischbacher C, McCartney G, et al. Increasingly Diverse: The Changing Ethnic Profiles of Scotland and Glasgow and the Implications for Population Health. Appl Spatial Analysis. 2019;12: 983–1009. doi:10.1007/s12061-018-9281-7

14. McKeigue PM, Colhoun HM. Evaluation of "stratify and shield" as a policy option for ending the COVID-19 lockdown in the UK. medRxiv. 2020; 2020.04.25.20079913. doi:10.1101/2020.04.25.20079913

15. Bunnik BAD van, Morgan ALK, Bessell P, Calder-Gerver G, Zhang F, Haynes S, et al. Segmentation and shielding of the most vulnerable members of the population as elements of an exit strategy from COVID-19 lockdown. medRxiv. 2020; 2020.05.04.20090597. doi:10.1101/2020.05.04.20090597

465

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

487

488

489

490

491

492




Fig 1. Incidence of severe and fatal COVID-19 in Scotland by age and sex: generalized additive models fitted to severe and fatal cases for males and females separately




Fig 2. Cross-validation of model chosen by stepwise regression using extended variable set: class-conditional distributions of weight of evidence

Footnote for Figure 2

For each individual, the risk prediction model outputs the posterior probability of being 496 a case, which can also be expressed as the posterior odds. Dividing the posterior odds 497 by the prior odds gives the likelihood ratio favouring case over non-case status for an 498 individual. The weight of evidence W is the logarithm of this ratio. The distributions of 499 W in cases and controls in the test data are plotted in Figure 2. For a classifier, the 500 further apart these curves are, the better the predictive performance. The expected 501 information for discrimination Λ is the average of the mean of the distribution of W in 502 cases and minus 1 times the mean of the distribution of W in controls. The 503 distributions have been adjusted by taking a weighted average to make them 504 mathematically consistent [11]. 505




Fig 3. Cross-validation of model chosen by stepwise regression using extended variable set: receiver operating characteristic curve

Footnote for Figure 3

The crude receiver operator characteristic (ROC) curve is computed by calculating at each value of the risk score the sensitivity and specificity of a classifier that uses this value as the threshold for classifying cases and non-cases. The C-statistic is the area under this curve, computed as the probability of correctly classifying a case/noncase pair using the score, evaluated over all possible such pairs in the dataset. 507

Tables

	$\begin{array}{c} \text{Controls} \\ (22089) \end{array}$	$\begin{array}{c} \text{Cases} \\ (2222) \end{array}$	Rate ratio (95% CI)	<i>p</i> -value
Ethnicity based on n	ame classificatio	on		
White	21081 (96%)	2169~(98%)		
South Asian	614 (3%)	35 (2%)	$0.53 \ (0.37, \ 0.76)$	4×10^{-4}
Other	303~(1%)	10 (0%)	$0.31 \ (0.17, \ 0.59)$	3×10^{-4}
SIMD quintile				
1 - most deprived	5323 (25%)	610 (28%)		
2	4513 (21%)	534 (24%)	1.00(0.88, 1.14)	1
3	3858(18%)	392(18%)	0.83(0.71, 0.96)	0.01
4	3784 (18%)	376(17%)	0.79(0.68, 0.92)	0.002
5 - least deprived	4049 (19%)	305(14%)	0.56(0.48, 0.67)	1×10^{-11}
Care home	801 (4%)	516 (23%)	14.9 (12.7, 17.5)	7×10^{-240}
Ethnicity based on S	cottish Morbidi	ty Record		
White	5903~(99%)	1172 (99%)		
South Asian	42 (1%)	9 (1%)	$0.81 \ (0.31, \ 2.10)$	0.7
Black	15 (0%)	2(0%)	0.34(0.04, 2.84)	0.3
Other	27(0%)	5(0%)	0.88(0.27, 2.84)	0.8

dia ith d f, .+i. ſ 1. : Table 1 ΤT . . .

TADIE 2. LIEQUEINES OF TISK FACTOR III CASES ALL	acen III CINNER	a diu cumunis, c	controus, by age group					
	0-39	0-39 years	40-59	40-59 years	60-74	60-74 years	75+	75+ years
	Controls (600)	Cases (60)	Controls (3519)	Cases (352)	Controls (5848)	Cases (585)	Controls (12122)	Cases (1225)
Care home	0 (0%)	1(2%)	4(0%)	9(3%)	38(1%)	50(9%)	759 (6%)	456 (37%)
Any prescription	274(46%)	50(83%)	1793(51%)	318(90%)	3906(67%)	556(95%)	8170(67%)	1204(98%)
Any admission	$133\ (22\%)$		$869\ (25\%)$	$209\ (59\%)$	$2207\ (38\%)$	442 $(76%)$	5872 (48%)	1034 (84%)
Any listed condition	53(9%)	30(50%)	$616\ (18\%)$	$194\ (55\%)$	1860(32%)	399(68%)	$5172 \ (43\%)$	976(80%)
No listed condition, other diagnosis	102(17%)	9(15%)	520(15%)	62~(18%)	909 ($16%$)	$95\ (16\%)$	1641(14%)	144(12%)
Diagnosis or prescription	305~(51%)	50~(83%)	$1899 \ (54\%)$	$333\ (95\%)$	$4026\ (69\%)$	569 (97%)	$8291 \ (68\%)$	$1218\ (99\%)$
Type 1 diabetes	4(1%)	3(5%)	19(1%)	15(4%)	31(1%)	6(1%)	27(0%)	10(1%)
Type 2 diabetes	3(0%)	2(3%)	151(4%)	$63\ (18\%)$	648 (11%)	148(25%)	$1515\ (12\%)$	$276\ (23\%)$
Other/unknown type	1 (0%)	4(7%)	18(1%)	9(3%)	36(1%)	5(1%)	$62\ (1\%)$	20(2%)
Ischaemic heart disease	1 (0%)	1 (2%)	87~(2%)	28 (8%)	463(8%)	113(19%)	$1651\ (14\%)$	311~(25%)
Other heart disease	1 (0%)	7~(12%)	88(3%)	60 (17%)	555 (9%)	171 (29%)	$2565\ (21\%)$	579~(47%)
Asthma or chronic airway disease	40 (7%)	23(38%)	344(10%)	91(26%)	793 $(14%)$	209(36%)	1915(16%)	407 (33%)
Chronic kidney disease or	(%0) 0	(%0) 0	4 (0%)	17~(5%)	11 (0%)	$18 \ (3\%)$	42~(0%)	$30 \ (2\%)$
Neurological (except epilepsy) or dementia	3(0%)	7~(12%)	39(1%)	31 (9%)	144 (2%)	80 (14%)	963 (8%)	361 (29%)
Liver disease	1 (0%)	(%0) 0	$13 \ (0\%)$	9(3%)	$19\ (0\%)$	9(2%)	$22\;(0\%)$	7(1%)
Immune deficiency or suppression	4(1%)	2 (3%)	$14\ (0\%)$	11 (3%)	$25 \ (0\%)$	$10 \ (2\%)$	35~(0%)	$9\ (1\%)$

Table 2. Frequencies of risk factors in cases and controls, by age group

			Univariate	late	Multivariate	riate
	Controls (22089)	Cases (2222)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Care home	801 (4%)	516(23%)	$14.9\ (12.7,\ 17.5)$	$7 imes 10^{-240}$	$7.4 \ (6.2,\ 8.9)$	1×10^{-105}
Any prescription Any admission	$14143 (64\%) \\ 9081 (41\%)$	$2128 \ (96\%)$ 1715 (77%)	$16.6\ (13.3,\ 20.6)$ $5.6\ (5.0\ 6.2)$	3×10^{-141} 0×10^{-213}	$6.3 \ (5.0, 8.0) \\ 1 \ 92 \ (1 \ 68 \ 2 \ 18)$	1×10^{-34} 4×10^{-23}
Type 1 diabetes	81(0%)	34(2%)	4.88(3.26, 7.31)	$1 imes 10^{-14}$	2.20(1.39, 2.50)	$8 imes 10^{-4}$
Type 2 diabetes	$2317\ (10\%)$	489 (22%)	2.58(2.30, 2.88)	$1 imes 10^{-60}$	$1.57\ (1.38,\ 1.78)$	$2 imes 10^{-12}$
Other/unknown type	117 (1%)	$38 \ (2\%)$	$3.89\ (2.69,\ 5.63)$	$6 imes 10^{-13}$	$2.01\ (1.33,\ 3.03)$	0.001
Ischaemic heart disease	$2202 \ (10\%)$	453 (20%)	2.40(2.14, 2.70)	$1 imes 10^{-49}$	$1.08 \ (0.94, \ 1.23)$	0.3
Other heart disease	$3209\ (15\%)$	817 (37%)	3.90(3.52, 4.32)	$3 imes 10^{-151}$	$1.42 \ (1.25, \ 1.60)$	4×10^{-8}
Asthma or chronic airway	$3092\ (14\%)$	730~(33%)	3.10(2.81, 3.42)	2×10^{-112}	$1.59\ (1.43,\ 1.78)$	1×10^{-16}
Chronic kidney disease or	57~(0%)	65 (3%)	$12.1\ (8.4,\ 17.4)$	$1 imes 10^{-40}$	$4.98\ (3.30,\ 7.50)$	$2 imes 10^{-14}$
Neurological (except epilepsy) or	1149 (5%)	479~(22%)	$5.5 \ (4.8, \ 6.2)$	$3 imes 10^{-158}$	$1.84 \ (1.59, \ 2.13)$	$9 imes 10^{-16}$
Liver disease	$55\ (0\%)$	$25 \ (1\%)$	$4.70\ (2.90,\ 7.62)$	3×10^{-10}	$1.65\ (0.96,\ 2.85)$	0.07
Immune deficiency or	78 (0%)	32 (1%)	$4.11 \ (2.72, \ 6.21)$	$2 imes 10^{-11}$	$1.17\ (0.71,\ 1.93)$	0.5
suppression						

Table 3. Associations of severe disease with listed conditions over all age groups

	Controls	Fatal cases
Age <60		
No scrip or diagnosis	1941~(44%)	3~(3%)
Scrip or diagnosis	2483~(56%)	104~(97%)
Age 60-74		
No scrip or diagnosis	1830(30%)	8(2%)
Scrip or diagnosis	4256 (70%)	339(98%)
Age $75+$		
No scrip or diagnosis	3832~(31%)	6(1%)
Scrip or diagnosis	8366 (69%)	1143 (99%)

Table 4. Proportions of fatal cases and matched controls without and with a dispensed prescription or hospital diagnosis, by age group

UDE J. ASSOCIATIONS OF SEVELE DISEASE WITH HOSPICAL DIAGNOSES IN 1881 3 YEARS, IN THOSE WITHOUT ANY INVERTIGATION	ansease wrun mospirar	ulagnoses III Ia	st o years, III tilose wit	mout any mou		
			Univariate		Multivariate	в
	Controls (14388)	Cases (623)	Rate ratio $(95\% \text{ CI})$	<i>p</i> -value	Rate ratio $(95\% \text{ CI})$	<i>p</i> -value
Ch.1 infectious	245 (2%)	48 (8%)	5.0(3.4, 7.4)	$6 imes 10^{-16}$	$1.54 \ (0.96, \ 2.48)$	0.07
Ch.2 Neoplasms	543(4%)	67 (11%)	3.56(2.61, 4.86)	1×10^{-15}	$2.25\ (1.55,\ 3.27)$	$2 imes 10^{-5}$
Ch.3 blood	165(1%)	23 $(4%)$	4.89(2.79, 8.58)	$3 imes 10^{-8}$	$1.42 \ (0.74, \ 2.73)$	0.3
Ch.4 Endocrine	155(1%)	27(4%)	4.38(2.64, 7.26)	$1 imes 10^{-8}$	$1.36\ (0.75,\ 2.46)$	0.3
Ch.5 Mental	215(1%)	54(9%)	5.6(3.8, 8.3)	$2 imes 10^{-18}$	$1.72 \ (1.06, \ 2.79)$	0.03
Ch.6 nervous	$130\;(1\%)$	$16 \; (3\%)$	$3.61\ (1.89,\ 6.87)$	1×10^{-4}	$2.38\ (1.16,\ 4.88)$	0.02
Ch.7 eye	714(5%)	55(9%)	$1.99\ (1.43,\ 2.77)$	$5 imes 10^{-5}$	1.65(1.14, 2.38)	0.008
Ch.8 ear	50(0%)	4(1%)	2.46(0.79, 7.68)	0.1	$1.62\ (0.47,\ 5.59)$	0.4
Ch.9 circulatory	226(2%)	$34\ (5\%)$	$3.51 \ (2.27, \ 5.45)$	$2 imes 10^{-8}$	$1.14 \ (0.67, \ 1.94)$	0.6
Ch.10 respiratory	164(1%)	41 (7%)	5.8(3.8, 8.9)	$9 imes 10^{-16}$	2.04(1.21, 3.44)	0.008
Ch.11 digestive	981 (7%)	$105\ (17\%)$	$2.83\ (2.20,\ 3.64)$	$6 imes 10^{-16}$	$1.47\ (1.09,\ 1.98)$	0.01
Ch.12 skin	170(1%)	18 (3%)	$2.10\ (1.23,\ 3.57)$	0.006	$0.69\ (0.36,\ 1.32)$	0.3
Ch.13 musculoskeletal	$601 \ (4\%)$	77~(12%)	$3.34 \ (2.49, 4.48)$	$9 imes 10^{-16}$	$1.65\ (1.17,\ 2.34)$	0.004
Ch.14 genitourinary	550~(4%)	$81 \ (13\%)$	$3.87\ (2.88,\ 5.20)$	$2 imes 10^{-19}$	$1.47\ (1.01,\ 2.14)$	0.04
Ch.15 Pregnancy	22 (0%)	(%0) 0	$0.00 \ (0.00, Inf)$	нц.	$0.00 \ (0.00, {\rm Inf})$	1
Ch.17 Congenital	$21 \ (0\%)$	4(1%)	$6.1\ (1.6,\ 22.9)$	0.007	$2.39\ (0.56,\ 10.28)$	0.2
Ch.18 Symptoms	853 (6%)	123(20%)	$3.98\ (3.12,\ 5.08)$	$2 imes 10^{-28}$	$1.56\ (1.13,\ 2.15)$	0.007
Ch.19 Injury	434~(3%)	$81 \ (13\%)$	$4.36\ (3.22,\ 5.91)$	$2 imes 10^{-21}$	$1.18\ (0.46,\ 3.03)$	0.7
Ch.20 External	494~(3%)	93~(15%)	$4.71\ (3.53,\ 6.29)$	$5 imes 10^{-26}$	$1.79\ (0.72,4.42)$	0.2
Ch.21 Health factors	872~(6%)	$99\ (16\%)$	$3.03\ (2.34,\ 3.92)$	$2 imes 10^{-17}$	$0.94\ (0.67,\ 1.32)$	0.7

Table 5. Associations of severe disease with hospital diagnoses in last 5 years, in those without any listed condition

			Univariate		Multivariate	e
	Controls (14388)	Cases (623)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
BNF 1 Gastro	2952~(21%)	330 (53%)	$5.1 \ (4.2, 6.1)$	2×10^{-66}	2.23(1.78, 2.80)	5×10^{-12}
BNF 2 Cardiovascular	3861(27%)	$334\ (54\%)$	3.92(3.24, 4.74)	4×10^{-45}	$2.07\ (1.66,\ 2.58)$	8×10^{-11}
BNF 3 Respiratory	556(4%)	68(11%)	3.15(2.33, 4.26)	1×10^{-13}	$1.34\ (0.94,\ 1.91)$	0.1
BNF 4 Nervous	$3234\ (22\%)$	$342\ (55\%)$	4.58(3.81, 5.50)	1×10^{-58}	$1.82\ (1.44,\ 2.30)$	$5 imes 10^{-7}$
BNF 5 Infections	1666(12%)	$182\ (29\%)$	$3.15\ (2.58,\ 3.86)$	6×10^{-29}	$1.32\ (1.04,\ 1.68)$	0.02
BNF 6 Endocrine	1289~(9%)	122 (20%)	2.80(2.20, 3.55)	4×10^{-17}	$1.19\ (0.89,1.59)$	0.2
BNF 7 Obstetrics	1056(7%)	79 (13%)	$1.90\ (1.45,\ 2.50)$	4×10^{-6}	$0.73 \ (0.53, 1.00)$	0.05
BNF 8 Malignant	153(1%)	16(3%)	2.17(1.22, 3.88)	0.009	0.85(0.44, 1.66)	0.6
BNF 9 Nutrition	$1327\ (9\%)$	168(27%)	4.37(3.48, 5.49)	4×10^{-37}	$1.71 \ (1.31, \ 2.23)$	$9 imes 10^{-5}$
BNF 10 Musculoskeletal	$1731\ (12\%)$	176(28%)	$2.89\ (2.36,\ 3.54)$	8×10^{-25}	$1.08\ (0.85,\ 1.37)$	0.5
BNF 11 Eye	006~(6%)	60(10%)	$1.57\ (1.16,\ 2.13)$	0.004	$0.72\ (0.51,\ 1.02)$	0.06
BNF 12 Ear	818(6%)	59(9%)	1.71(1.27, 2.31)	$5 imes 10^{-4}$	0.65(0.46, 0.92)	0.01
BNF 13 Skin	1643(11%)	167(27%)	$3.17\ (2.57,\ 3.91)$	$3 imes 10^{-27}$	1.32(1.02, 1.71)	0.03
BNF 14 Other	$1687\ (12\%)$	202(32%)	4.13(3.36, 5.08)	4×10^{-41}	$1.91 \ (1.49, \ 2.46)$	4×10^{-7}

	Cases / controls	Crude C- statistic	Adjusted C- statistic	Crude Λ (bits)	Adjusted Λ (bits)	Test log- likelihood (nats)
Demographic only	$2109 \ / \ 20417$	0.697	0.696	0.52	0.46	0.0
$\tilde{\text{Demographic}}$ +	2109 /	0.793	0.782	0.96	0.89	482.2
listed conditions Extended variable set	20417 2109 / 20417	0.836	0.839	1.44	1.50	912.2

 Table 7. Prediction of severe COVID-19: cross-validation of models chosen by stepwise regression

Supplementary tables

			IIminoto		Multiversite	
			U III V AL	aue		LIAUE
	Controls (4119)	Cases (412)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Care home	4 (0%)	10(2%)	25.0(7.8, 79.7)	$5 imes 10^{-8}$	$6.6\ (1.7,\ 25.1)$	0.006
Any prescription	2067 (50%)	368 (89%)	$9.6\;(6.9,13.3)$	$6 imes 10^{-41}$	5.0(3.5, 7.2)	$1 imes 10^{-18}$
Any admission	1002 (24%)	$239\ (58\%)$	$4.54 \ (3.66, 5.63)$	$2 imes 10^{-43}$	$1.62\ (1.25,\ 2.10)$	$3 imes 10^{-4}$
Type 1 diabetes	23(1%)	18(4%)	$9.8 \ (5.2, \ 18.4)$	1×10^{-12}	4.29(2.04, 8.99)	$1 imes 10^{-4}$
Type 2 diabetes	154(4%)	$65 \ (16\%)$	5.4(3.9, 7.5)	$6 imes 10^{-25}$	$2.84 \ (1.97, 4.09)$	$2 imes 10^{-8}$
Other/unknown type	$19\ (0\%)$	$13 \ (3\%)$	$7.4 \ (3.6, \ 15.0)$	$3 imes 10^{-8}$	$4.28\ (1.96,\ 9.37)$	$3 imes 10^{-4}$
Ischaemic heart disease	88(2%)	29(7%)	3.66(2.34, 5.72)	1×10^{-8}	0.76(0.43, 1.33)	0.3
Other heart disease	89(2%)	$67 \ (16\%)$	$9.2\ (6.5,\ 13.1)$	$1 imes 10^{-35}$	$2.81 \ (1.81, 4.36)$	4×10^{-6}
Asthma or chronic airway	384(9%)	114(28%)	$3.84 \ (3.00, 4.90)$	$8 imes 10^{-27}$	$1.81 \ (1.37, 2.40)$	$4 imes 10^{-5}$
disease						
Chronic kidney disease or transplant recipient	4(0%)	17(4%)	$42.5\ (14.3,\ 126.3)$	$2 imes 10^{-11}$	$22.3 \ (5.1, \ 98.5)$	4×10^{-5}
Neurological (except epilepsv) or dementia	$42 \ (1\%)$	$38 \ (9\%)$	$10.1 \ (6.4, \ 16.0)$	1×10^{-22}	$3.67\ (2.09,\ 6.44)$	6×10^{-6}
Liver disease	$14\ (0\%)$	9(2%)	$7.3 \ (3.0, \ 17.7)$	$1 imes 10^{-5}$	$1.61\ (0.54,4.75)$	0.4
Immune deficiency or	$18 \ (0\%)$	$13 \ (3\%)$	$7.2\ (3.5,\ 14.7)$	$6 imes 10^{-8}$	$0.35\ (0.10,\ 1.27)$	0.1
suppression						

 Table 8. Associations of severe disease with listed conditions in those aged less than 60

			Univariate	late	Multivariate	riate
	Controls (5848)	Cases (585)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	<i>p</i> -value
Care home	38 (1%)	50(9%)	$19.0\ (11.6,\ 31.3)$	$5 imes 10^{-31}$	$9.2\ (5.3,\ 16.0)$	$2 imes 10^{-15}$
Any prescription	3906(67%)	556(95%)	$10.8 \ (7.3, \ 16.0)$	3×10^{-33}	$4.59 \ (3.02, \ 6.98)$	9×10^{-13}
Any admission	$2207\ (38\%)$	442 $(76%)$	$5.3\ (4.4,\ 6.5)$	$1 imes 10^{-60}$	2.22(1.76, 2.81)	$2 imes 10^{-11}$
Type 1 diabetes	31 (1%)	6(1%)	2.38(0.99, 5.76)	0.05	0.80(0.27, 2.33)	0.7
Type 2 diabetes	$648\ (11\%)$	148(25%)	$2.77\ (2.26,\ 3.41)$	3×10^{-22}	$1.67\ (1.33,\ 2.09)$	$9 imes 10^{-6}$
Other/unknown type	$36\;(1\%)$	5(1%)	$1.73\ (0.67,\ 4.43)$	0.3	$0.63\ (0.22,\ 1.85)$	0.4
Ischaemic heart disease	463(8%)	113(19%)	$2.87 \ (2.28, 3.62)$	4×10^{-19}	$1.20\ (0.92,\ 1.57)$	0.2
Other heart disease	555 (9%)	171 (29%)	$4.15\ (3.38,\ 5.09)$	4×10^{-42}	$1.44\ (1.13,\ 1.85)$	0.004
Asthma or chronic airway	793 (14%)	209(36%)	$3.68 \ (3.05, 4.45)$	$2 imes 10^{-41}$	$1.84 \ (1.49, \ 2.26)$	$1 imes 10^{-8}$
disease						
Chronic kidney disease or transplant recipient	11 (0%)	18 (3%)	$17.6\ (8.1,\ 38.1)$	4×10^{-13}	$8.2\ (3.5,\ 19.2)$	$2 imes 10^{-6}$
Neurological (except epilepsv) or dementia	144~(2%)	80~(14%)	$6.4 \ (4.8, \ 8.6)$	4×10^{-35}	$2.54 \ (1.80, \ 3.58)$	1×10^{-7}
Liver disease	$19\ (0\%)$	9(2%)	$4.84\ (2.17,\ 10.80)$	$1 imes 10^{-4}$	$1.73\ (0.67,\ 4.44)$	0.3
Immune deficiency or	$25\;(0\%)$	10(2%)	$4.00\ (1.92,\ 8.33)$	$2 imes 10^{-4}$	$0.86\ (0.34,\ 2.20)$	0.8
suppression						

 Table 9. Associations of severe disease with listed conditions in those aged 60-74 years

			Univariate	iate	Multivariate	riate
	Controls (12122)	Cases (1225)	Rate ratio (95% CI)	<i>p</i> -value	Rate ratio (95% CI)	p-value
Care home	759 (6%)	456(37%)	$14.3\ (12.0,\ 17.0)$	2×10^{-204}	7.3 (6.0, 8.9)	1×10^{-90}
Any prescription	8170(67%)	1204(98%)	$40.3\ (25.6,\ 63.3)$	$8 imes 10^{-58}$	11.4(7.1, 18.4)	1×10^{-23}
Any admission	$5872 \ (48\%)$	$1034\ (84\%)$	$6.4\ (5.5,\ 7.6)$	$9 imes 10^{-109}$	1.72(1.41, 2.10)	$7 imes 10^{-8}$
Type 1 diabetes	27(0%)	10(1%)	4.13(2.00, 8.55)	$1 imes 10^{-4}$	$2.20\ (0.96,\ 5.05)$	0.06
Type 2 diabetes	$1515\ (12\%)$	276~(23%)	$2.14\ (1.85,\ 2.48)$	$8 imes 10^{-24}$	1.33(1.13, 1.57)	$6 imes 10^{-4}$
Other/unknown type	$62\;(1\%)$	$20 \ (2\%)$	$3.82\ (2.29,\ 6.37)$	$3 imes 10^{-7}$	$2.23\ (1.25,\ 3.98)$	0.007
Ischaemic heart disease	1651 (14%)	311 (25%)	2.18(1.89, 2.50)	$1 imes 10^{-27}$	$1.07 \ (0.91, \ 1.26)$	0.4
Other heart disease	$2565\ (21\%)$	579(47%)	$3.45 \ (3.05, 3.90)$	$2 imes 10^{-86}$	$1.32 \ (1.13, 1.54)$	4×10^{-4}
Asthma or chronic airway	1915(16%)	407 (33%)	2.71(2.38, 3.08)	$1 imes 10^{-50}$	$1.43 \ (1.24, \ 1.66)$	$2 imes 10^{-6}$
disease						
Chronic kidney disease or transplant recipient	42~(0%)	$30 \ (2\%)$	$7.5\ (4.6,\ 12.1)$	2×10^{-16}	$3.47\ (2.05,\ 5.90)$	4×10^{-6}
Neurological (except epilepsy) or dementia	$963 \ (8\%)$	$361 \ (29\%)$	4.97 $(4.31, 5.74)$	$7 imes 10^{-107}$	$1.60\ (1.34,\ 1.90)$	$1 imes 10^{-7}$
Liver disease	$22 \ (0\%)$	7(1%)	$3.19\ (1.35,\ 7.54)$	0.008	$1.37\ (0.52,\ 3.57)$	0.5
Immune deficiency or	$35 \ (0\%)$	9 (1%)	$2.57\ (1.23,\ 5.36)$	0.01	$1.66\ (0.73,\ 3.76)$	0.2
suppression						

Table 10. Associations of severe disease with listed conditions in those aged 75 years and over

May 30,	2020

te associations of severe disease with hospital diagnoses by ICD subchapters in those without any listed conditions: rows	ith $p < 0.001$ and at least 50 cases and controls
Table 11. Univariate associations of sev	retained are those with $p < 0.001$ and a

	Controls (14388)	Cases (623)	Rate ratio (95% CI)	<i>p</i> -value
Intestinal Infectious Diseases Bacterial And Viral Infectious Agents Melanoma And Other Malignant Neoplasms Of Skin Malignant Neoplasms Of Breast Malignant Neoplasms Of Male Genital Organs	$\begin{array}{c} 94 \ (1\%) \\ 77 \ (1\%) \\ 1117 \ (1\%) \\ 58 \ (0\%) \\ 58 \ (0\%) \end{array}$	$\begin{array}{c} 17 \ (3\%) \\ 13 \ (2\%) \\ 12 \ (2\%) \\ 1 \ (0\%) \\ 5 \ (1\%) \end{array}$	$\begin{array}{c} 4.19 & (2.20, \ 7.96) \\ 3.74 & (1.86, \ 7.52) \\ 3.11 & (1.52, \ 6.36) \\ 0.39 & (0.05, \ 2.96) \\ 2.08 & (0.75, \ 5.75) \end{array}$	$\begin{array}{c} 1 \times 10^{-5} \\ 2 \times 10^{-4} \\ 0.002 \\ 0.4 \\ 0.2 \end{array}$
Malignant Neuroendocrine Tumors Benign Neoplasms, Except Benign Neuroendocrine Tumors Nutritional Anemias Aplastic And Other Anemias And Other Bone Marrow Failure Syndromes Metabolic Disorders	$\begin{array}{c} 60 & (0\%) \\ 182 & (1\%) \\ 79 & (1\%) \\ 73 & (1\%) \\ 101 & (1\%) \end{array}$	$\begin{array}{c} 11 \ (2\%) \\ 23 \ (4\%) \\ 5 \ (1\%) \\ 11 \ (2\%) \\ 20 \ (3\%) \end{array}$	$\begin{array}{c} 5.1 & (2.2, 11.4) \\ 3.33 & (2.00, 5.52) \\ 2.03 & (0.73, 5.64) \\ 8.2 & (3.3, 20.6) \\ 4.50 & (2.49, 8.14) \end{array}$	$\begin{array}{c} 1 \times 10^{-4} \\ 3 \times 10^{-6} \\ 0.2 \\ 7 \times 10^{-6} \end{array}$
Mental Disorders Due To Known Physiological Conditions Mental And Behavioral Disorders Due To Psychoactive Substance Use Episodic And Paroxysmal Disorders Nerve, Nerve Root And Plexus Disorders Disorders Of Eyelid, Lacrimal System And Orbit	$\begin{array}{c} 74 \ (1\%) \\ 109 \ (1\%) \\ 55 \ (0\%) \\ 75 \ (1\%) \\ 46 \ (0\%) \end{array}$	$\begin{array}{c} 33 \ (5\%) \\ 13 \ (2\%) \\ 7 \ (1\%) \\ 9 \ (1\%) \\ 6 \ (1\%) \end{array}$	$\begin{array}{c} 11.1 \ (6.0, \ 20.9) \\ 2.32 \ (1.22, \ 4.41) \\ 3.45 \ (1.25, \ 9.51) \\ 3.63 \ (1.59, \ 8.27) \\ 2.43 \ (0.91, \ 6.48) \end{array}$	5×10^{-14} 0.01 0.02 0.002 0.002
Disorders Of Lens Disorders Of Choroid And Retina Glaucoma Cerebrovascular Diseases Diseases Of Veins, Lymphatic Vessels And Lymph Nodes, Not Elsewhere Classified	$\begin{array}{c} 616 \ (4\%) \\ 72 \ (1\%) \\ 65 \ (0\%) \\ 78 \ (1\%) \\ 76 \ (1\%) \end{array}$	$\begin{array}{c} 47 \ (8\%) \\ 4 \ (1\%) \\ 4 \ (1\%) \\ 13 \ (2\%) \\ 9 \ (1\%) \end{array}$	$\begin{array}{c} 1.93 & (1.35, 2.75) \\ 1.73 & (0.57, 5.26) \\ 1.86 & (0.61, 5.71) \\ 4.07 & (1.97, 8.38) \\ 2.15 & (0.99, 4.67) \end{array}$	$egin{array}{c} 3 imes 10^{-4} \ 0.3 \ 0.3 \ 1 imes 10^{-4} \ 1 imes 10^{-4} \ 0.05 $
Other And Unspecified Disorders Of The Circulatory System Influenza And Pneumonia Other Acute Lower Respiratory Infections Diseases Of Esophagus, Stomach And Duodenum Hernia	$\begin{array}{c} 49 & (0\%) \\ 62 & (0\%) \\ 65 & (0\%) \\ 313 & (2\%) \\ 247 & (2\%) \end{array}$	$11 (2\%) \\ 13 (2\%) \\ 23 (4\%) \\ 30 (5\%) \\ 22 (4\%) \\$	$\begin{array}{c} 4.78 & (2.15, 10.64) \\ 5.5 & (2.6, 11.8) \\ 9.7 & (5.0, 18.8) \\ 2.15 & (1.39, 3.32) \\ 2.34 & (1.42, 3.87) \end{array}$	$\begin{array}{c} 1\times 10^{-4}\\ 9\times 10^{-6}\\ 1\times 10^{-11}\\ 5\times 10^{-4}\\ 9\times 10^{-4} \end{array}$

May 30, 2020

Noninfective Enteritis And Colitis		9(1%)	$3.94\ (1.68,\ 9.27)$	0.002
Other Diseases Of Intestines	468(3%)	54 (9%)	$3.21 \ (2.27, 4.54)$	4×10^{-11}
Disorders Of Gallbladder, Biliary Tract And Pancreas	110 (1%) 83 (1%)	13 (2%)	$2.12\ (1.09,\ 4.13)$	0.03 $\varepsilon \sim 10^{-4}$
Utilier Diseases Of The Digesture bystelli Infrations Of The Chin And Curbantanoons Tissue	(021) 00 67 (002)	12 (270) 2 (102)	0.40 (1.12, 1.04) 0.21 (1.05 5 10)	
Infections Of 1 he 5km And 5ubcutaneous 1 issue	04 (U%)	Q (1%)		0.04
Other Disorders Of The Skin And Subcutaneous Tissue	46~(0%)	10(2%)	$4.82 \ (2.12, \ 10.94)$	$2 imes 10^{-4}$
Inflammatory Polyarthropathies	47~(0%)	11 (2%)	$5.6\ (2.5,\ 12.7)$	$3 imes 10^{-5}$
Osteoarthritis	263 (2%)	29~(5%)	$3.02\ (1.90,\ 4.80)$	$3 imes 10^{-6}$
Other Joint Disorders	97~(1%)	10 (2%)	$2.40\ (1.14,\ 5.04)$	0.02
Other Dorsopathies	$85\ (1\%)$	7(1%)	$2.05\ (0.85,\ 4.94)$	0.1
Other Soft Tissue Disorders	$115 \ (1\%)$	16 (3%)	$3.09\ (1.68,\ 5.66)$	$3 imes 10^{-4}$
Disorders Of Bone Density And Structure	$55\ (0\%)$	10 (2%)	$6.0\ (2.2,\ 16.4)$	$6 imes 10^{-4}$
Acute Kidney Failure And Chronic Kidney Disease	117(1%)	29 (5%)	$7.2 \ (4.0, \ 12.8)$	$2 imes 10^{-11}$
Urolithiasis	44(0%)	6(1%)	$2.69\ (1.03,\ 7.05)$	0.04
Other Diseases Of The Urinary System	241 (2%)	42(7%)	$4.47\ (2.96,\ 6.76)$	1×10^{-12}
Diseases Of Male Genital Organs	$159\ (1\%)$	$14\ (2\%)$	$2.17\ (1.17,\ 4.02)$	0.01
Noninflammatory Disorders Of Female Genital Tract	85(1%)	7(1%)	$1.75\ (0.75,\ 4.09)$	0.2
Symptoms And Signs Involving The Circulatory And Respiratory Systems	173~(1%)	15 (2%)	$2.01\ (1.10,\ 3.69)$	0.02
Symptoms And Signs Involving The Digestive System And Abdomen	277 (2%)	33~(5%)	$2.46\ (1.62,3.74)$	$2 imes 10^{-5}$
Symptoms And Signs Involving The Nervous And Musculoskeletal Systems	$120\ (1\%)$	$38\ (6\%)$	$11.0\ (6.2,\ 19.3)$	1×10^{-16}
Symptoms And Signs Involving The Genitourinary System	$182\ (1\%)$	25(4%)	$3.22\ (1.94,\ 5.36)$	$7 imes 10^{-6}$
Symptoms And Signs Involving Cognition, Perception, Emotional State And Behavior	$81 \ (1\%)$	$21 \ (3\%)$	$4.99\ (2.75,\ 9.07)$	1×10^{-7}
General Symptoms And Signs	212 (1%)	37~(6%)	$4.00\ (2.60,\ 6.14)$	$3 imes 10^{-10}$
Abnormal Findings On Diagnostic Imaging And In Function Studies, Without Diagnosis	64~(0%)	16~(3%)	$6.6\ (3.2,\ 13.5)$	$2 imes 10^{-7}$
Injuries To The Head	$99\ (1\%)$	19 (3%)	$3.79\ (2.09,\ 6.89)$	$1 imes 10^{-5}$
Injuries To The Wrist, Hand And Fingers	52~(0%)	5(1%)	$2.04\ (0.74,\ 5.60)$	0.2
Injuries To The Hip And Thigh Injuries To The Knee And Lower Lee	67 (0%) 44 (0%)	$22 (4\%) \\ 9 (1\%)$	$\begin{array}{c} 8.3 \ (4.3, \ 16.1) \\ 3.85 \ (1.65, \ 9.01) \end{array}$	$5 imes 10^{-10}$ 0.002
	(11/2) 21	(11+) 0	0.00 (+.00, 0.0+)	100.0

Complications Of Surgical And Medical Care, Not Elsewhere Classified	94 (1%)	14 (2%)	$3.69 \ (1.86, 7.33)$	$2 imes 10^{-4}$
Supping, Iripping, Stumbing And Fails	243 (2%)	(0%8) 20	9.1(3.9, 1.0)	$T \times 10^{-5}$
Misadventures To Patients During Surgical And Medical Care	$42 \ (0\%)$	$13 \ (2\%)$	$10.7\ (4.2,\ 27.1)$	$6 imes 10^{-7}$
Surgical And Other Medical Procedures As The Cause Of Abnormal Reaction Of The	115(1%)	16 (3%)	$3.79\ (2.00,\ 7.21)$	$5 imes 10^{-5}$
Patient, Or Of Later Complication, Without Mention Of Misadventure At The Time				
Of The Procedure				

	log rate ratio	p-value
Care home resident	1.89	2×10^{-89}
SIMD - quintile 1 as reference		
SIMD.quintile 2	0.00	1
SIMD.quintile 3	-0.08	0.4
SIMD.quintile 4	-0.21	0.02
SIMD.quintile 5 - least deprived	-0.33	0.001
Diabetes - non-diabetic as reference		
Other diabetes type	0.52	0.1
Type 1	0.45	0.07
Type 2	0.21	0.004
Other heart disease	0.25	1×10^{-4}
Asthma or chronic airway disease	0.27	$6 imes 10^{-6}$
Chronic kidney disease or transplant recipient	0.57	1×10^{-8}
Neurological (except epilepsy) or dementia	0.42	$1 imes 10^{-8}$
Liver disease	0.52	0.07
Any admission	0.52	2×10^{-13}
Any prescription	1.22	4×10^{-19}
BNF 1 Gastro	0.25	7×10^{-5}
BNF 2 Cardiovascular	0.11	0.1
BNF 4 Nervous	0.28	3×10^{-5}
BNF 5 Infections	0.16	0.005
BNF 6 Endocrine	0.29	$3 imes 10^{-6}$
BNF 7 Obstetrics	-0.17	0.01
BNF 9 Nutrition	0.39	4×10^{-11}
BNF 14 Other	0.25	2×10^{-5}

Table 1	2.	Stepwise	regression:	variables	retained	in	model	for	severe	disease	